Immunic to Participate in Scientific and Investor Conferences in March
March 4-7: 34th Annual Meeting of the Society for Virology. Two abstracts have been accepted for abstract talk presentations at this conference in Hamburg, Germany. The presentations will be accessible on the 'Events and Presentations' section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Title: Orally Bioavailable RORγ/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity
Presenting Author: Friedrich Hahn, Ph.D., Institute for Clinical and Molecular Virology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
Abstract Talk: O 081
Session: Antiviral therapy and resistance I
Date: March 6, 2025
Time: 9:30-9:45 am CET (3:30-3:45am ET)
Title: Novel Vidofludimus-Based DHODH Inhibitors Containing Carboxylic Acid Bioisosters with Superior Broad-Spectrum Antiviral Activity
Presenting Author: Alexandra Herrmann, Ph.D., Manager Translational Pharmacology, Immunic
Abstract Talk: O 112
Session: Antiviral therapy and resistance II
Date: March 7, 2025
Time: 11:00-11:15am CET (5:00-5:15am ET)
March 10-12: Leerink Partners Global Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, will participate in a fireside chat on Wednesday, March 12, at 10:00 am ET during this conference in Miami. A webcast will be available on the 'Events and Presentations' section of Immunic's website at: https://ir.imux.com/events-and-presentations.
Dr. Vitt, Glenn Whaley, Chief Financial Officer, and Jessica Breu, Vice President Investor Relations and Communications, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Leerink representative or Jessica Breu at: [email protected].
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis, progressive multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor-related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease as well as inflammatory bowel disease, Graft-versus-Host-Disease and weight management. IMU-381, which currently is in preclinical testing, is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains 'forward-looking statements' that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in scientific and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, increasing inflation, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, including the ability to satisfy the minimum average price and trading volume conditions required to receive funding in tranche 2 and 3 of the January 2024 private placement, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the Company's products or product candidates, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned 'Risk Factors,' in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the SEC on February 22, 2024, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.
Contact Information
Immunic, Inc.
+49 89 2080 477 09
[email protected]
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
[email protected]
US Media Contact
KCSA Strategic Communications
Caitlin Kasunich
+1 212 896 1241
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Analog Devices Shares Jump After Blowout Quarter and Upbeat Forecast
This article first appeared on GuruFocus. Aug 20 - Analog Devices (NASDAQ:ADI) gained roughly 4% on Wednesday after reporting fiscal third-quarter results that topped Wall Street expectations and offering stronger-than-expected guidance for the current quarter. The move came even as most other semiconductor stocks traded lower. Warning! GuruFocus has detected 11 Warning Signs with ADI. Revenue in the third quarter rose about 4% above consensus and exceeded the high end of the company's guided range. Communications and Consumer segments delivered notable strength, with sales beating analyst forecasts by 15% and 6%, respectively. Management projected fiscal fourth-quarter revenue to grow 4% sequentially, which is 6% ahead of consensus expectations. Analysts were quick to weigh in. Wells Fargo reiterated an Equal Weight rating with a $235 price target, noting solid bookings and pointing to forward visibility as a key factor for recovery heading into fiscal 2026. Evercore maintained its Outperform rating with a $280 price target, citing the revenue beats and robust demand outlook. Truist kept its Hold rating and $219 price target, highlighting that tariffs and trade fluctuations still cloud the broader market backdrop. With macro uncertainty continuing, investors seem buoyed by the fact that Analog Devices is able to move through the changing environment and still show a high level of demand in the most important markets.
Miami Herald
5 minutes ago
- Miami Herald
Leading Global Drone Propulsion Solutions Manufacturer ePropelled Expands U.S. Operations
LACONIA, NH / ACCESS Newswire / August 20, 2025 / Global manufacturer of propulsion andintelligent controls for multi-domain uncrewed systems, ePropelled, Inc. has significantly expanded its operations to become the first U.S.-based drone component solutions manufacturer with a supply chain that meets Department of Defense compliance standards. The soon to be 24,000 square foot facility in Laconia, New Hampshire, will annually produce hundreds of thousands of uncrewed motors and controllers for air, land and sea use as early as 2026. Meanwhile, in parallel, ePropelled is planning to open an additional manufacturing facility overseas to supply international customers. "We began production late last year and have been scaling up ever since," said Nick Grewal, ePropelled Founder, Chairman and CEO. "This expansion of our U.S. production hub will shorten the turnaround time from order to shipment and get them into the hands of our customers faster. This expansion, coupled with a new domestic rare earth supplier and NDAA compliance, sets us apart and is attractive for many of our customers." The Laconia facility will grow to more than 350 employees who will use state-of-the-art equipment to produce a range of advanced electric propulsion motor and controller solutions for drones from start to finish. This includes winding the coils, sealing/curing, rare-earth magnet rotator assemblies, precision balancing, motor and controller assembly, software installation and quality control for the Sparrow, Falcon and Hercules Series. The Sparrow Series solution range from 160Kv-2900Kv and 260W to 7000W, designed for lightweight UAVs. The Falcon Series includes high-power UAV motors like the iAPM600, producing up to 10kW at 5,000RPM. The Hercules Series features starter-generator systems, such as the SG12000, providing up to 14 kW at 9,000 RPM for hybrid UAV applications. In 2026, ePropelled will be vertically integrated with in-house lamination stack production and a machine shop. "The opening of our new manufacturing facility marks an exciting milestone for ePropelled as we expand our ability to serve customers in the U.S. and worldwide," said Richard Edwards, ePropelled Director of Operations. "This U.S.-based state-of-the-art site is equipped with advanced production capabilities and rigorous quality-control systems, all certified to ISO 9001:2015 standards. By combining the very latest technology with our commitment to excellence, we ensure every product meets the highest levels of performance and reliability." ePropelled operates worldwide, including engineering, innovation and production facilities in the UK and India, serving a broad customer base that spans aerospace, defense, industrial automation, automotive and maritime industries. The company's technologies can be used in mission-critical applications, including long-endurance surveillance drones, robotic ground vehicles and autonomous marine vessels. Its compliance with international defense standards and focus on domestically manufactured components make it especially attractive to governments and OEMs seeking secure, export-ready solutions. About ePropelledBased in Laconia, New Hampshire, USA, ePropelled, Inc. is a leading global technology provider specializing in smart propulsion and energy management systems for uncrewed vehicles for air, land and sea. Founded in 2018, ePropelled holds 49 patents and serves customers worldwide from its New Hampshire headquarters and manufacturing center, supported by R&D and operations facilities in the UK and India. ePropelled products are engineered to maximize performance, reduce energy consumption, and drive a faster transition to a sustainable future. For more information, contact ePropelled at info@ call 603-236-7444, or visit ### Contact Information Kristen Lestock kristen@ SOURCE: ePropelled, Inc. press release
Yahoo
9 minutes ago
- Yahoo
UBS sees buy opportunity in Microsoft as pricing changes boost cloud revenues
-- UBS said in a note on Wednesday that Microsoft's latest pricing and licensing changes are likely to drive stronger cloud revenues, reinforcing its Buy rating on the stock. 'Last week, Microsoft (NASDAQ:MSFT) announced a new pricing and licensing model that partners described as 'significant' and 'very aggressive,' prompting us to explore the change in detail,' UBS analysts wrote. The bank said Microsoft is 'standardizing pricing across most of its customer tiers on EA contract types, with partners consistent in their feedback that this results in a net price increase.' The changes, effective Nov. 1, will apply to Microsoft's Online Services suite, including Azure, Microsoft 365/Office 365, and Dynamics 365. UBS estimated these products represent about 55% of revenues. Government and education contracts, as well as on-premise products, are exempt. According to partners cited by UBS, the net price increase ranges between '3-6% to 10-14%.' UBS stated that it assumes the new pricing was reflected in Microsoft's guidance and that the firm now has 'marginally more confidence in our outlook for total c/c revenue growth of 14% in FY26E.' Analysts cautioned, however, that the benefits may be gradual because the increases apply as contracts renew and do not cover Microsoft's largest global accounts. The bank also noted that 'partners flagged a series of separate pricing/licensing changes that Microsoft has been making on its on-prem suite that we conclude could have accelerated Azure migration activity of late.' UBS kept its $650 price target and Buy rating on MSFT unchanged, citing the company's strong positioning in artificial intelligence. 'We still view the stock as being reasonably priced given how levered Microsoft is to the AI phenomenon,' the analysts said. Related articles UBS sees buy opportunity in Microsoft as pricing changes boost cloud revenues Clients buying into summer rally, bracing for later pullback, says BofA's Hartnett After soaring 149%, this stock is back in our AI's favor - & already +25% in July
